Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 17/20 | 0.64 |
| ▸ | JAK3 | P52333 | 15/20 | 0.64 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14675794 | 1.00 | JAK2 (0.64) | JAK2JAK3NTRK1JAK1KCNH2 | |
| SCHEMBL4972280 | 0.96 | JAK2 (0.60) | JAK2JAK3NTRK1JAK1KCNH2 | |
| SCHEMBL4973056 | 0.92 | JAK2 (0.67) | JAK2JAK3NTRK1JAK1KCNH2 | |
| SCHEMBL4974079 | 0.89 | JAK2 (0.64) | JAK2JAK3NTRK1JAK1KCNH2 | |
| SCHEMBL4980198 | 0.86 | JAK2 (0.64) | JAK2JAK3 | |
| SCHEMBL4972182 | 0.84 | JAK2 (0.48) | JAK2JAK3NTRK1JAK1KCNH2 | |
| SCHEMBL4972548 | 0.81 | JAK2 (0.46) | JAK2JAK3NTRK1JAK1KCNH2 | |
| SCHEMBL4972196 | 0.81 | JAK2 (0.45) | JAK2JAK3NTRK1KCNH2 | |
| SCHEMBL16824760 | 0.80 | JAK2 (0.55) | JAK2JAK3NTRK1JAK1KCNH2 | |
| SCHEMBL16824759 | 0.80 | JAK2 (0.55) | JAK2JAK3NTRK1JAK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034311-B2 | Pyridin-2(1 H)-one derivatives as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-05-19 | — | — | US | disclosed |
| US-20140271543-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2014-09-18 | — | — | US | disclosed |
| EP-2739616-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS | Almirall, S.A. (ES) | 2014-06-11 | — | — | EP | disclosed |
| WO-2013017461-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-02-07 | — | — | WO | disclosed |
| WO-2008132502-A1 | PYRAZOLYL-AMINO-SUBSTITUTED PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140271543-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | JAK2 2/4885JAK3 3/4885NTRK1 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.